Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...